Nemaura Medical Performance
| NMRDDelisted Stock | USD 0.93 0.01 1.06% |
The company secures a Beta (Market Risk) of -1.72, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Nemaura Medical are expected to decrease by larger amounts. On the other hand, during market turmoil, Nemaura Medical is expected to outperform it. Nemaura Medical right now secures a risk of 0.0%. Please verify Nemaura Medical treynor ratio, kurtosis, period momentum indicator, as well as the relationship between the downside variance and day median price , to decide if Nemaura Medical will be following its current price movements.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Nemaura Medical has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Nemaura Medical is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 17.7 M | |
| Total Cashflows From Investing Activities | -539.2 K | |
| Free Cash Flow | -9 M |
Nemaura |
Nemaura Medical Relative Risk vs. Return Landscape
If you would invest 93.00 in Nemaura Medical on August 24, 2024 and sell it today you would earn a total of 0.00 from holding Nemaura Medical or generate 0.0% return on investment over 90 days. Nemaura Medical is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Nemaura, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nemaura Medical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nemaura Medical's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Nemaura Medical, and traders can use it to determine the average amount a Nemaura Medical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| NMRD |
Based on monthly moving average Nemaura Medical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nemaura Medical by adding Nemaura Medical to a well-diversified portfolio.
Nemaura Medical Fundamentals Growth
Nemaura Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Nemaura Medical, and Nemaura Medical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nemaura Pink Sheet performance.
| Return On Equity | -7.24 | ||||
| Return On Asset | -0.49 | ||||
| Current Valuation | 22.58 M | ||||
| Shares Outstanding | 28.9 M | ||||
| Price To Earning | (707.14) X | ||||
| Price To Book | 122.56 X | ||||
| Price To Sales | 804.62 X | ||||
| Revenue | 77.04 K | ||||
| EBITDA | (8.17 M) | ||||
| Cash And Equivalents | 14.75 M | ||||
| Cash Per Share | 0.61 X | ||||
| Total Debt | 20.03 M | ||||
| Book Value Per Share | (0.55) X | ||||
| Cash Flow From Operations | (8.45 M) | ||||
| Earnings Per Share | (0.39) X | ||||
| Total Asset | 14.56 M | ||||
| Retained Earnings | (51.88 M) | ||||
| Current Asset | 9.55 M | ||||
| Current Liabilities | 658.01 K | ||||
About Nemaura Medical Performance
By analyzing Nemaura Medical's fundamental ratios, stakeholders can gain valuable insights into Nemaura Medical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Nemaura Medical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Nemaura Medical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York. Nemaura Med operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 32 people.Things to note about Nemaura Medical performance evaluation
Checking the ongoing alerts about Nemaura Medical for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Nemaura Medical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nemaura Medical is not yet fully synchronised with the market data | |
| Nemaura Medical has some characteristics of a very speculative penny stock | |
| Nemaura Medical has a very high chance of going through financial distress in the upcoming years | |
| Nemaura Medical currently holds 20.03 M in liabilities. Nemaura Medical has a current ratio of 0.97, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Nemaura Medical until it has trouble settling it off, either with new capital or with free cash flow. So, Nemaura Medical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nemaura Medical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nemaura to invest in growth at high rates of return. When we think about Nemaura Medical's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 77.04 K. Net Loss for the year was (14.14 M) with loss before overhead, payroll, taxes, and interest of (1.48 M). | |
| Nemaura Medical currently holds about 14.75 M in cash with (8.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.61. | |
| Roughly 48.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Nemaura Medical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nemaura Medical's stock is overvalued or undervalued compared to its peers.
- Examining Nemaura Medical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nemaura Medical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nemaura Medical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nemaura Medical's pink sheet. These opinions can provide insight into Nemaura Medical's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Consideration for investing in Nemaura Pink Sheet
If you are still planning to invest in Nemaura Medical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Nemaura Medical's history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |